GlassScriptPhysician profile
David B Greenberg
NPI 1053413500
$96,725.86
in general payments reported to CMS, 2019-2025
72 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,937 · 2020: $2,629 · 2021: $14K · 2022: $8,631 · 2023: $21K · 2024: $24K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Food and Beverage: $6,256 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,665.00 |
| Food and Beverage | $6,256.41 |
| Education | $256.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $48,679.13 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Seagen INC. | $39,433.67 | 2019-2023 | Adcetris, Padcev |
| Astellas Pharma US INC | $1,254.71 | 2020-2025 | Padcev, Cresemba, Xtandi |
| Novartis Pharmaceuticals Corporation | $643.52 | 2019-2025 | |
| Gilead Sciences, INC. | $489.26 | 2021-2025 | Trodelvy |
| Abbvie INC. | $455.50 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $436.89 | 2019-2025 | Opdualag, Opdivo |
| Merck Sharp & Dohme LLC | $408.17 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $302.04 | 2019-2025 | Tecvayli, Erleada, Talvey |
| Eisai INC. | $289.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $282.90 | 2021-2025 | Enhertu, Lynparza, Tagrisso |
| Janssen Pharmaceuticals, INC | $264.74 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $223.77 | 2020-2024 | Verzenio, Jaypirca, Retevmo |
| Intera Oncology, INC | $203.24 | 2024-2025 | Intera |
| Celgene Corporation | $194.16 | 2019-2025 | Reblozyl, Opdualag |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $179.35 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $175.79 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Genzyme Corporation | $173.09 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.34 | 2019-2023 | |
| Taiho Oncology, INC. | $167.83 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $162.13 | 2021-2025 | Monoferric, Cosela |
| Pfizer INC. | $144.63 | 2019-2025 | |
| Genmab U.S., INC. | $140.27 | 2024-2025 | Epkinly |
| Genentech USA, INC. | $133.56 | 2019-2025 | Itovebi, Venclexta, Rozlytrek |
| Emd Serono, INC. | $104.62 | 2019-2025 | |
| Kite Pharma, INC. | $102.60 | 2021-2025 | Yescarta |
| Comsort, INC | $100.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $96.65 | 2023-2024 | Libtayo |
| Stemline Therapeutics INC. | $74.49 | 2024-2025 | Orserdu |
| Exelixis INC. | $61.77 | 2019-2025 | Cabometyx |
| Sirtex Medical INC | $58.31 | 2020-2025 | Sir-Spheres Microspheres |
| Springworks Therapeutics, INC. | $56.97 | 2024-2025 | Ogsiveo |
| Servier Pharmaceuticals LLC | $52.13 | 2024-2025 | |
| Geron Corporation | $51.04 | 2025 | Rytelo |
| Array Biopharma INC | $49.97 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Agios Pharmaceuticals, INC. | $48.16 | 2022-2024 | Pyrukynd |
| Jazz Pharmaceuticals INC. | $45.74 | 2021-2025 | |
| Beigene USA, INC. | $45.38 | 2022-2023 | Brukinsa |
| Adc Therapeutics America, INC. | $42.22 | 2024 | |
| Tesaro, INC. | $34.91 | 2019 | |
| Abbott Laboratories | $34.91 | 2019 | |
| Mirati Therapeutics, INC. | $34.58 | 2023-2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $33.56 | 2022-2025 | Onivyde |
| Puma Biotechnology, INC. | $31.98 | 2021-2025 | |
| Myovant Sciences INC. | $31.96 | 2022 | |
| Sumitomo Pharma America, INC. | $31.45 | 2023-2024 | Orgovyx |
| Pharmacyclics LLC, An Abbvie Company | $28.69 | 2020-2021 | |
| Epizyme, INC. | $28.63 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $28.58 | 2019 | |
| Alexion Pharmaceuticals, INC. | $28.49 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.45 | 2019-2021 | |
| Amgen INC. | $26.14 | 2019-2023 | Kyprolis |
| Blueprint Medicines Corporation | $26.00 | 2022-2023 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $21.32 | 2025 | |
| Foundation Medicine, INC. | $19.14 | 2023 | |
| Emmaus Medical, INC. | $18.52 | 2022 | |
| Sobi, INC | $17.76 | 2024 | |
| Menarini Silicon Biosystems, INC. | $17.68 | 2024 | |
| Novocure INC. | $17.45 | 2025 | Optune Lua (Novottf-200t) |
| Rigel Pharmaceuticals, INC. | $16.84 | 2023 | Tavalisse, Rezlidhia |
| Kyowa Kirin, INC. | $16.40 | 2023 | Poteligeo |
| G1 Therapeutics, INC. | $15.78 | 2023 | Cosela |
| Aadi Bioscience, INC. | $15.54 | 2023 | Fyarro |
| Organon LLC | $15.33 | 2021 | |
| Octapharma USA, INC. | $15.01 | 2022 | |
| Pharmaessentia USA Corporation | $14.77 | 2023 | Besremi |
| Morphosys, US INC. | $14.53 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.39 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.18 | 2019 | |
| Acceleron Pharma, INC. | $13.64 | 2021 | |
| Apellis Pharmaceuticals, INC. | $12.71 | 2023 | Empaveli |
| Clovis Oncology, INC. | $6.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.